Search results
Results from the WOW.Com Content Network
The rate of cancer recurrence is determined by many factors, including age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors. [2] [3] [4] If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original ...
Minimal residual disease (MRD), also known as Molecular residual disease, is the name given to small numbers of cancer cells that remain in a person either during or after treatment when the patient is in remission (no symptoms or signs of disease). Sensitive molecular tests are either in development or available to test for MRD.
Multiple myeloma is the second-most prevalent blood cancer (10%) after non-Hodgkin's lymphoma. [154] It represents about 1.8% of all new cancers and 2.1% of all cancer deaths. [7] Multiple myeloma affects slightly more men than women.
The spontaneous regression and remission from cancer was defined by Everson and Cole in their 1966 book as "the partial or complete disappearance of a malignant tumour in the absence of all treatment, or in the presence of therapy which is considered inadequate to exert significant influence on neoplastic disease." [1]
Relapse is a term to describe returning symptoms of the disease after a period of remission. In cancer-treatment, doctors usually avoid the term "cured" and instead prefer the term "no evidence of disease" (NED) to refer to a complete remission of cancer, which does not rule out the possibility of relapse. [3] [4]
Thus, relapse is applied only for those plasmodial species that have hypnozoites in the life cycle, such as Plasmodium vivax and P. ovale. On the other hand, recrudescence means that circulating, multiplying parasites are detected after having persisted in the bloodstream (or elsewhere) at undetectable levels for a period of time, as merozoites ...
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.